ROVI announces the agreement with Sandoz to distribute and market its Enoxaparin biosimilar

ROVI –Agreement with Sandoz to distribute and market its Enoxaparin biosimilar For further information: Investor Relations (Tel: +34 91 244 44 22) Marta Campos Martínez [email protected] ROVI announces the agreement with Sandoz to distribute and market its Enoxaparin biosimilar Madrid, 11 th June 2018 – Laboratorios Farmaceúticos Rovi S.A. (ROVI:SM) signed a licensing agreement with Sandoz , a division of Novartis AG and a global leader in generic pharmaceuticals and biosim ilars, to distribute and market its enoxaparin biosimilar in 14 countries/regions (Australia, New Zealand, Philippines, Hong Kong, Singapore, Vietnam , Malaysia, Canada, South Africa, Brazil, Colombia, Argentina, Mexico and Cen tral America). Under the terms of the agreement, Sandoz has the exclusive ri ghts for three of these countries, which are Hong Kong, Singapore and Vietnam. ROVI’s enoxaparin sodium is a biosimilar to Sanofi’ s Lovenox® and Clexane®, which is an anticoagulant medication that belongs t o low molecular weight heparin class. It is used to treat and prevent deep vein thrombosis and pulmonary embolism. As of March 2018, ROVI has achi eved national authorisation for their biosimilar of enoxaparin in 16 European markets, and has commenced marketing in Germany and UK. Juan López-Belmonte Encina, ROVI’s Chief Executive Officer said, “ROVI is very excited with our agreement with Sandoz, the global leader in biosimilars where our enoxaparin biosimilar will find an excellent gr owth. Sandoz is an excellent collaboration partner to expand ROVI’s global footp rint and become a leader in the low-molecular-weight heparin field” ROVI –Agreement with Sandoz to distribute and market its Enoxaparin biosimilar About ROVI ROVI is a fully integrated Spanish specialty pharmaceutical company engaged in the research, development, in-licensing, manufactur ing and marketing of small molecule and specialty biologic drugs. The Company has a diversified portfolio of products that it markets in Spain through its sp ecialized sales force, calling on specialist physicians, hospitals and pharmacies. ROVI’s portfolio of 30 principal marketed products is currently anchored b y the internally-developed, second generation low molecular weight heparin, Bem iparin. ROVI’s research and development pipeline is focused primarily on the expansion of applications, indications and alternative mechanisms of action fo r the heparin-derived products and other glycosaminoglycans and on the de velopment of new controlled release mechanisms based on ISM® technol ogy, with the aim of obtaining new pharmaceutical products that enable t he regular administration of formulations which are administered daily in chr onic and prolonged treatments. ROVI manufactures the active biological ingredient (Bemiparin) for its principal proprietary products and for injectab le pharmaceutical products developed by its in-house research team, and utiliz es its state-of-the-art filling and packaging capabilities to provide a broad array of toll manufacturing services to leading international pharmaceutical co mpanies, primarily in the area of pre-filled syringes. In addition, ROVI prov ides contract manufacturing and packaging services of solid oral pharmaceutical dosage forms, using the most enhanced technology, Roller Compaction. Additi onal information about ROVI is available on the company’s website: www.rovi.es .

The release as fetched from its publisher. rovi.es ↗